Home > Insider Trading > Filing (0001144204-13-010336)

Filing Details

Accession Number:: 0001144204-13-010336
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2013-02-20 20:19:30
Reporting Period:: 2013-02-15

Filing Date:: 2013-02-20
Accepted Time:: 2013-02-20 20:19:30
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1232524	Jazz Pharmaceuticals Plc	JAZZ	Pharmaceutical Preparations (2834)	981032470

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1253886	G Patrick Enright	Co Longitude Capital Partners Llc 800 El Camino Real, Suite 220 Menlo Park CA 94025		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Ordinary Shares	Disposition	2013-02-15	18,703	$58.41	1,599,597	No	4	S	Indirect	By Longitude Venture Partners, L.P.
Ordinary Shares	Disposition	2013-02-15	196	$59.04	1,599,401	No	4	S	Indirect	By Longitude Venture Partners, L.P.
Ordinary Shares	Disposition	2013-02-15	375	$58.41	32,067	No	4	S	Indirect	By Longitude Capital Associates, L.P.
Ordinary Shares	Disposition	2013-02-15	4	$59.04	32,063	No	4	S	Indirect	By Longitude Capital Associates, L.P.
Ordinary Shares	Disposition	2013-02-19	46,451	$58.13	1,552,950	No	4	S	Indirect	By Longitude Venture Partners, L.P.
Ordinary Shares	Disposition	2013-02-19	921	$58.13	31,142	No	4	S	Indirect	By Longitude Capital Associates, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By Longitude Venture Partners, L.P.
No	4	S	Indirect	By Longitude Venture Partners, L.P.
No	4	S	Indirect	By Longitude Capital Associates, L.P.
No	4	S	Indirect	By Longitude Capital Associates, L.P.
No	4	S	Indirect	By Longitude Venture Partners, L.P.
No	4	S	Indirect	By Longitude Capital Associates, L.P.

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Ordinary Shares	2,250	Direct

Footnotes

Securities were sold pursuant to a 10b5-1 trading plan.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.00 to $58.96, inclusive. The reporting person undertakes to provide to Jazz Pharmaceuticals plc, any security holder of Jazz Pharmaceuticals plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.03 to $59.05, inclusive. The reporting person undertakes to provide to Jazz Pharmaceuticals plc, any security holder of Jazz Pharmaceuticals plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.00 to $58.34, inclusive. The reporting person undertakes to provide to Jazz Pharmaceuticals plc, any security holder of Jazz Pharmaceuticals plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The reporting person disclaims beneficial ownership of the securities of Jazz Pharmaceuticals plc held by Longitude Venture Partners, L.P. and Longitude Capital Associates, L.P., except to the extent of his pecuniary interest therein.
These restricted stock units were granted pursuant to Jazz Pharmaceuticals plc's 2007 Equity Incentive Plan on August 9, 2012. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units will vest in full on August 9, 2013.